Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 4
2012 9
2013 57
2014 234
2015 390
2016 518
2017 565
2018 573
2019 431
2020 400
2021 352
2022 248
2023 169
2024 131
2025 138
2026 57

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,736 results

Results by year

Filters applied: . Clear all
Page 1
Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB, Kelley D, Childs-Kean LM. Chahine EB, et al. Ann Pharmacother. 2018 Apr;52(4):352-363. doi: 10.1177/1060028017741508. Epub 2017 Nov 8. Ann Pharmacother. 2018. PMID: 29115151 Review.
POLARIS-2 failed to demonstrate that sofosbuvir/velpatasvir/voxilaprevir for 8 weeks was noninferior to sofosbuvir/velpatasvir for 12 weeks in patients with HCV genotype 1 through 6 who had no prior exposure to direct-acting antivirals (DAAs). ...POLARIS-4 de …
POLARIS-2 failed to demonstrate that sofosbuvir/velpatasvir/voxilaprevir for 8 weeks was noninferior to sofosbuvir/velpatasvir …
Sofosbuvir: A comprehensive profile.
Lababidi JM, Kabil MF, Azzazy HME. Lababidi JM, et al. Profiles Drug Subst Excip Relat Methodol. 2025;50:1-41. doi: 10.1016/bs.podrm.2024.10.003. Epub 2025 Jan 9. Profiles Drug Subst Excip Relat Methodol. 2025. PMID: 39855774 Review.
Sofosbuvir, a nucleotide analogue, is an antiviral medication that belongs to the class of direct-acting antivirals (DAAs). ...This chapter offers a comprehensive examination of sofosbuvir, including its nomenclature, physiochemical attributes, synthes …
Sofosbuvir, a nucleotide analogue, is an antiviral medication that belongs to the class of direct-acting antivirals (DA …
Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.
Dumortier J, Bailly F, Pageaux GP, Vallet-Pichard A, Radenne S, Habersetzer F, Gagnieu MC, Grangé JD, Minello A, Guillaud O, Kamar N, Alric L, Leroy V. Dumortier J, et al. Nephrol Dial Transplant. 2017 Dec 1;32(12):2065-2071. doi: 10.1093/ndt/gfw348. Nephrol Dial Transplant. 2017. PMID: 27760839 Free article.
Over the last few years, second-generation direct-acting antivirals have been revolutionary in the treatment of hepatitis C, and sofosbuvir (SOF) is the backbone of most modern treatment strategies. ...Dose of RBV was reduced in two patients (16.7%) during antivi …
Over the last few years, second-generation direct-acting antivirals have been revolutionary in the treatment of hepatitis C, and s …
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
Sayad B, Sobhani M, Khodarahmi R. Sayad B, et al. Arch Med Res. 2020 Aug;51(6):577-581. doi: 10.1016/j.arcmed.2020.04.018. Epub 2020 Apr 29. Arch Med Res. 2020. PMID: 32387040 Free PMC article.
There are no specific treatments for COVID-19 as yet, though a number are under evaluation, including experimental antivirals. Sofosbuvir, the clinically approved anti-hepatitis C virus (HCV) drug, is also capable of suppressing other families of positive-strand RNA …
There are no specific treatments for COVID-19 as yet, though a number are under evaluation, including experimental antivirals. Sof …
Antiviral treatment of hepatitis C.
Feeney ER, Chung RT. Feeney ER, et al. BMJ. 2014 Jul 7;348:g3308. doi: 10.1136/bmj.g3308. BMJ. 2014. PMID: 25002352 Free PMC article. Review.
The NS3/4A inhibitor simeprevir and NS5B inhibitor sofosbuvir have recently been licensed and can reduce the length of antiviral treatment, improve response rates, and allow for interferon-free regimens for some HCV genotypes. Several other newer direct acting an …
The NS3/4A inhibitor simeprevir and NS5B inhibitor sofosbuvir have recently been licensed and can reduce the length of antiviral …
Synergistic antiviral activity of Sofosbuvir and type-I interferons (alpha and beta) against Zika virus.
Snyder B, Goebel S, Koide F, Ptak R, Kalkeri R. Snyder B, et al. J Med Virol. 2018 Jan;90(1):8-12. doi: 10.1002/jmv.24932. Epub 2017 Sep 22. J Med Virol. 2018. PMID: 28851097
As a proof of concept toward combination therapeutic strategy against ZIKV, combinations of host-targeted (Interferon-alpha and Interferon-beta) and direct acting (Sofosbuvir) antivirals were evaluated in a hepatic cell line (Huh7) using a Cytoprotection (CP) assay. …
As a proof of concept toward combination therapeutic strategy against ZIKV, combinations of host-targeted (Interferon-alpha and Interferon-b …
Sofosbuvir: first global approval.
Keating GM, Vaidya A. Keating GM, et al. Drugs. 2014 Feb;74(2):273-82. doi: 10.1007/s40265-014-0179-7. Drugs. 2014. PMID: 24442794 Review.
Oral sofosbuvir has been approved in the US for the treatment of chronic hepatitis C as a component of a combination antiviral regimen. In addition, the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of sof …
Oral sofosbuvir has been approved in the US for the treatment of chronic hepatitis C as a component of a combination antiviral …
Long-term efficacy and safety of sofosbuvir-based direct-acting antiviral regimens in paediatric patients with hepatitis C virus infection: an international registry study.
Gonzalez-Peralta RP, Wen JW, Hardikar W, Karnsakul WW, Whitworth S, Lin CH, Indolfi G, Rosenthal P, Balistreri W, Schwarz KB, Honegger JR, Zhang X, Svarovskaia EC, Suri V, Kersey K, Leung DH. Gonzalez-Peralta RP, et al. Lancet Child Adolesc Health. 2025 Apr;9(4):248-254. doi: 10.1016/S2352-4642(25)00028-8. Lancet Child Adolesc Health. 2025. PMID: 40113366
This study aimed to assess the efficacy and long-term effects of sofosbuvir-based direct-acting antiviral regimens on growth and development in the paediatric population. METHODS: In this international, multicentre, observational registry study, children aged 3-17 y …
This study aimed to assess the efficacy and long-term effects of sofosbuvir-based direct-acting antiviral regimens on growth a …
Sofosbuvir and daclatasvir.
Hessel MH, Cohen AF, Rissmann R. Hessel MH, et al. Br J Clin Pharmacol. 2016 Sep;82(3):878-9. doi: 10.1111/bcp.13011. Epub 2016 Jun 12. Br J Clin Pharmacol. 2016. PMID: 27198488 Free PMC article. No abstract available.
3,736 results